Insights On Drug Development

  1. From Cell Bank To Clinic Faster: GMP Manufacturing & Characterization 7/28/2026

    Accelerate your path to the clinic with an integrated, risk-based cell banking strategy that delivers speed, quality, and regulatory confidence at every stage.

  2. Target Product Profile (TPP) Explained 7/27/2026

    Learn how to best align your development strategy, guide cross-functional decisions, and build a clear pathway from discovery to successful commercialization.

  3. Drug Development Readiness: Interactive Checklist And RACI 7/27/2026

    Early decisions can have long-lasting consequences for development timelines, cost, risk, and overall probability of success. Engaging the appropriate disciplines early helps avoid downstream surprises and rework.

  4. Drug Development Plan Explained: DPP Templates And Examples 7/27/2026

    Only 6.7% of Phase 1 drugs reach approval. A well-structured Drug Development Plan (DDP) can meaningfully improve your odds — learn exactly how to build one.

  5. Ask Us Anything: Cy Credille On Fewer Setbacks, Faster To IND 7/25/2026

    Cy Credille, Group Leader in process chemistry at Cambrex Longmont, on the setbacks that come as standard in early development — and why a team that has seen them all before is the fastest route to the IND finish line.

  6. Ask Us Anything: Cy Credille On Continuity From Discovery To Commercialization 7/24/2026

    Learn how we balance discovery and development as an asset scales, and how the One Cambrex model keeps the original process scientists attached to a molecule from first kilos through NDA.

  7. Ask Us Anything: Eric Fang On Lithiation Chemistry 7/24/2026

    Eric Fang, General Manager of Snapdragon Chemistry, on why lithiation chemistry resists batch scale-up — and how a decade spent understanding static mixing lets Snapdragon carry these reactions from milligrams to metric tons.

  8. Ask Us Anything: Eric Fang On New Challenges In Pharma Development 7/24/2026

    Eric Fang on meeting new pharmaceutical development challenges with a two-part investment — technology that answers R&D questions faster, and scientists given the support to tackle what technology can't.

  9. Ask Us Anything: Erik Feldmann On Advancing Peptide Development 7/24/2026

    Erik Feldmann, Technical Director, on the analytical challenges of proteins, peptides, and oligonucleotides — and why he starts every method-development problem by understanding what the customer is trying to achieve.

  10. Ask Us Anything: Hannah McLachlan on Crystallization In Peptide Development 7/24/2026

    Hannah McLachlan, Project Scientist IV at Cambrex Edinburgh, on what crystallization screening delivers for peptide therapeutics — more stable material, higher purity, and a molecule clients can store without specialist infrastructure.